{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.31","upperLimit":"144.3","value":"86.06"},{"groupId":"OG001","lowerLimit":"138.5","upperLimit":"255.9","value":"188.2"},{"groupId":"OG002","lowerLimit":"191.8","upperLimit":"315.6","value":"246.1"},{"groupId":"OG003","lowerLimit":"284.6","upperLimit":"581.7","value":"406.9"},{"groupId":"OG004","lowerLimit":"18.05","upperLimit":"388.3","value":"83.72"},{"groupId":"OG005","lowerLimit":"190.9","upperLimit":"283.2","value":"232.5"},{"groupId":"OG006","lowerLimit":"253.9","upperLimit":"411.1","value":"323.1"},{"groupId":"OG007","lowerLimit":"240.9","upperLimit":"362.2","value":"295.4"},{"groupId":"OG008","lowerLimit":"198.5","upperLimit":"304.0","value":"245.6"},{"groupId":"OG009","lowerLimit":"182.6","upperLimit":"299.8","value":"234.0"}]}],"title":"Day 1 (n=6, 10, 26, 13, 4, 3, 25, 23, 18, 15)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.13","upperLimit":"202.6","value":"131.3"},{"groupId":"OG001","lowerLimit":"178.9","upperLimit":"253.1","value":"212.8"},{"groupId":"OG002","lowerLimit":"166.2","upperLimit":"330.1","value":"234.2"},{"groupId":"OG003","lowerLimit":"375.0","upperLimit":"711.0","value":"516.4"},{"groupId":"OG004","lowerLimit":"22.82","upperLimit":"897.8","value":"143.1"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"286.2","upperLimit":"358.9","value":"320.5"},{"groupId":"OG007","lowerLimit":"248.5","upperLimit":"431.9","value":"327.6"},{"groupId":"OG008","lowerLimit":"205.0","upperLimit":"461.8","value":"307.7"},{"groupId":"OG009","lowerLimit":"281.0","upperLimit":"408.8","value":"338.9"}]}],"title":"Day 15 (n=6, 9,15,9, 3, 1, 16, 17, 13, 10)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"24"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"15"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 15 milligram (mg) on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG000","title":"Pimasertib (MSC1936369B) 15mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 30 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG001","title":"Pimasertib (MSC1936369B) 30mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG002","title":"Pimasertib (MSC1936369B) 60mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 90 mg on Day 1 and 15 of cycle 1 until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG003","title":"Pimasertib (MSC1936369B) 90mg"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 45 mg on Day 1 and 15 of cycle 1 until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG004","title":"Pimasertib (MSC1936369B) 45mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 60 mg on Day 1 and 15 of cycle 1 until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG005","title":"Pimasertib (MSC1936369B) 60mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 and 15 of cycle 1 until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG006","title":"TNBC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 and 15 of cycle 1 until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG007","title":"NSCLC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 and 15 of cycle 1 until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG008","title":"CRC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 and 15 of cycle 1 until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG009","title":"MEL: Pimasertib 60mg Once Daily"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetic (PK) analysis set. Here \"n\" signifies the number of subjects evaluable at the specific time points.","reportingStatus":"POSTED","timeFrame":"Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts","title":"Maximum Observed Plasma Concentration (Cmax) for Pimasertib (MSC1936369B)","type":"SECONDARY","unitOfMeasure":"nanogram/millilitre (ng/mL)"}